CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
triamcinolone acetonide (Triesence®)drug
Likely dose
triamcinolone acetonide (Triesence®) 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01789320
NCT01789320Phase 2Completed
CompareCT.gov

Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis

Clearside Biomedical, Inc.·interventional·Posted Feb 12, 2013·Updated Feb 21, 2021

In Brief

A Phase 2 clinical trial evaluating triamcinolone acetonide (Triesence®) for Uveitis and 4 related conditions. Completed, enrolled 11 participants across 3 sites.

Detailed Summary

This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 12, 2013
Enrollment StartFeb 1, 2013
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 13.4 years ago

Interventions

triamcinolone acetonide (Triesence®)drug

4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space